Therefore, instead of synthesizing novel modulators, an alternative approach is to explore the possibility of repurposing FDA-approved tyrosine kinase inhibitors (TKIs) to resensitize ABCB1- or ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic agents [17,18]. This evidence concerns the gene ABCG2 and cancer.